OurIgGglycanlibraryisamixtureofnonfucosylatedandfucosylated,bi-antennaryglycanstandardswithvariablesialylationreleasedfromhumanIgGantibodyglycoprotein.Theyareavailableunlabeledandlabeledwithavarietyoftags.

WealsosupplyanIgGglycoproteinstandardforuseduringglycanreleaseandlabeling.

“Glycosylationcansignificantlyaffecttheinvivosafetyandefficacyprofilesoftherapeuticrecombinantmonoclonalantibodies(rMAbs).Inparticular,glycanscanhaveamarkedinfluenceonIgGFceffectorfunctionsandchangesinantibodyglycosylationareamajorcauseofbatch-to-batchvariABIlityduringproduction.Forthesereasons,itisessentialtomeasureandcontrolantibodyglycosylationaccuratelyandreliably.”ThisintroductionwascopiedfromDr.DarylFernandes’articleDemonstratingComparabilityofAntibodyGlycosylationduringBiomanufacturing

Sources: TheIgGglycanlibraryintheseproductsarereleasedfromanIgGstandardthatispurifiedfromhumanserum.IgGexistsinavarietyofglycoformscontainingbi-antennaryoligosaccharideswithvariablesialylation.

Form: Dry.Driedbycentrifugalevaporationfromanaqueoussolution.

Amountsupplied
    CLIBN-IGG-01      25µgs–unlabeled
    CAB-IGG-01          200pmol–2-ABlabeled
    CAPTS-IGG-01     10pmol–APTSlabeled
    CPROC-IGG-02    50pmol–procainamidelabeled
    CPM-IGG-01         20MSruns–permethylated
    CPM-C13-IGG-01  20MSruns–permethylatedwithheavy(13C)MeI

PermethylatedIgGglycanstandardsforMSanalysis
Massspectrometry(MS)isausefultoolindeterminingthemolecularweightsbutthesensitivitycanbelowespeciallywheretherearemanydifferentstructures.Carbohydratesoftencontaincarboxy,amino,sulphate,andphosphategroups.Thenatureandthepositionofthesegroupsontheresidue,aswellasthepositionofthisresiduewithintheglycanmaybedifficulttodetermine.Permethylationofglycansconvertshydrogengroupstomethylgroupswhichrenderstheglycanshydrophobic;theconversionstabilisessialicacidsandcanincreasesignalintensityinmassmeasurements.

WenowofferaLudgerTagapermethylatedIgGglycanlibrarytouseasasystemsuitabilitystandardduringMSanalysis.WealsoofferaC13versionwhichcanbeusedasaninternalstandardinthesameMALDIchipspotasyourC12-labelledpermethylatedglycans.

MassspectrumofpermethylatedIgGN-GlycansstandardreleasedfromHumanIgGantibodybyN-Modehydrazinolysis.AnalysisperformedonBrukerAutoflexMALDI-Ion

Purity: >90%pureasassessedbyacombinationof1H-NMRandHPLC,andCE

Storage: -20˚Cbothbeforeandafterdissolution.Theproductsarestableforatleast5yearsassupplied.
ViewCertificateofStabilty

Shipping: Theproductcanbeshippedatambientwhendry.Afterdissolution,shipondryice.

Handling: Allowtheunopenedvialtoreachambienttemperatureandtapunopenedonasolidsurfacetoensurethatmostofthelyophilizedmaterialisatthebottomofthevial.Gentlyremovethecap,addthedesiredvolumeofreconstitutionmedium,re-capandmixthoroughlytobringalltheoligosaccharideintosolution.Formaximalrecoveryofoligosaccharide,ensurethatthecapliningisalsorinsedandcentrifugethereconstitutedvialbrieflybeforeuse.Ensurethatanyglass,plasticwareorsolventsusedarefreeofglycosidasesandenvironmentalcarbohydrates.MinimiseexposuretoelevatedtemperaturesorextremesofpH.HightemperaturesandlowpHwillcausedesialylation.HighpHwillcauseepimerisationofthereducingterminusGlcNAc.

Safety: Thisproductisnon-hazardousandhasbeenpurifiedfromnaturalsourcescertifiedtobefreeofallhazardousmaterialincludingpathogenicBIOLOGicalagents.
DownloadNon-hazardousMSDS

References

BeyerB,SchusterM,JungbauerA,LinggN.MicroheterogeneityofRecombinantAntibodies:AnalyticsandFunctionalImpact.BiotechnolJ.2018Jan;13(1).doi:10.1002/biot.201700476.Epub2017Sep25.Review.

ShaS,AgarabiC,BrorsonK,LeeDY,YoonS.N-GlycosylationDesignandControlofTherapeuticMonoclonalAntibodies.TrendsBiotechnol.2016Oct;34(10):835-846.doi:10.1016/j.tibtech.2016.02.013.Epub2016Mar22.Review

LiuL.AntibodyglycosylationanditsimpactonthepharmacokineticsandpharmacodynamicsofmonoclonalantibodiesandFc-fusionproteins.JPharmSci.2015Jun;104(6):1866-1884.doi:10.1002/jps.24444.Epub2015Apr14.

JefferisR.Recombinantantibodytherapeutics:theimpactofglycosylationonmechanismsofaction.TrendsPharmacolSci.2009Jul;30(7):356-62.doi:10.1016/j.tips.2009.04.007.Epub2009Jun22.Review.

JefferisR.Glycosylationofrecombinantantibodytherapeutics.BiotechnolProg21:pp11-16,2005

FernandesD.DemonstratingComparabilityofAntibodyGlycosylationduringBiomanufacturing.EuropeanBiopharmaceuticalReview.Summer2005.pp106-110